Clinical Trial Update: Impact of Peptides and Chelators on Somatostatin Receptor Antagonists [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the impact of peptides and chelators on somatostatin receptor antagonists for neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Neuroendocrine Tumors | Phase 2 | Status: UNKNOWN